BioSpace News Archive

Matinas BioPharma Holdings, Inc. announced that on March 21, 2024, the Company received written notification from the NYSE American LLC stating that the Company has regained compliance with the NYSE American’s continued listing standards.

Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company developing and commercializing drug products to treat critically ill patients, announced that it has entered into a license agreement with Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”), a global pharmaceutical company, to commercialize a first-in-class innovative drug Centhaquine in India.

Humacyte, Inc. (Nasdaq: HUMA) today announced financial results for the fourth quarter and year ended December 31, 2023 and highlighted recent corporate accomplishments in advancing the investigational Human Acellular Vessel (HAV) closer to planned U.S. market launch.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne’s Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation.

Outlook Therapeutics, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion concerning the authorization of ONS-5010/LYTENAVA.

BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Oral Explanation scheduled for March 19 at the Committee for Medicinal Products for Human Use (CHMP) for lecanemab, which is currently under review by the European Medicines Agency (EMA), did not take place due to procedural reasons at EMA.

MorphoSys AG announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the proposed acquisition of MorphoSys by Novartis AG, following the expiration of the HSR Act waiting period.

ANGLE plc is pleased to announce its participation at the 14th European Breast Cancer Conference being held in Milan, Italy on 20 to 22 March 2024.

Zylox-Tonbridge Medical Technology Co., Ltd., a leading medical device company in the peripheral and neurovascular interventional market in China, announced its annual financial results for 2023.

The shareholders in Orexo AB, reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Friday 26 April 2024, at 16.00 pm in Orexo’s facilities at Rapsgatan 7E in Uppsala, Sweden.